COVID-19 Vaccine Trials
COVID-19 Prevention
Not SpecifiedActive
Key Facts
About DM Clinical Research
DM Clinical Research operates a network of clinical trial sites, functioning as both a site management organization (SMO) and a service provider to sponsors and CROs. Headquartered in Houston with a reported 700+ employees, the company has built an 18+ year track record conducting trials across multiple therapeutic areas. Its business model leverages direct patient recruitment, including an ambassador program, and provides full-service clinical research execution, with a notable involvement in COVID-19 vaccine trials as part of the #HoustonFightsCOVID initiative. The company appears to be a private, revenue-generating services firm in the clinical research sector.
View full company profileOther COVID-19 Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Intranasal COVID Vaccine | Virpax Pharmaceuticals | Research |
| SARS-CoV-2 Vaccine | Epygen Biotech | Not Disclosed |
| COVAXIN | Bharat Biotech | Commercial |
| iNCOVACC | Bharat Biotech | Commercial |
| IRT Platform (e.g., COVID-19) | Biological Mimetics | Research/Pre-clinical |
| Replicon RNA COVID-19 Vaccine | BIKEN Group | Preclinical/Development |
| Convidecia Air® (XBB.1.5 Variant) | CanSino Biologics | Approved |
| COVID-19 Vaccine | Recbio Technology | Not specified |
| COMIRNATY® (BNT162b2) | Fosun Pharma | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| Recombinant Protein COVID-19 Vaccine | Sinopharm | Approved |
| COVID-19 mRNA Vaccine (SYS6006) | CSPC Innovation Pharmaceutical | Marketed |